Published [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year]
– 13-week U.S. Part II look is evaluating the efficacy, safety and tolerability of oral miniature molecule GLP-1R agonist ASC30, a as soon as-day-to-day pill, in 100 participants with diabetes.
– Topline records from the Part II look are anticipated within the third quarter of 2026.
HONG KONG, April 26, 2026 /PRNewswire/ — Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) publicizes this day completion of enrollment in its 13-week U.S. Part II look ( NCT07321678 ) evaluating ASC30, an oral miniature molecule GLP-1 receptor (GLP-1R) agonist, for the remedy of form 2 diabetes mellitus (T2D). T2D is the second indication for ASC30, following its first indication of obesity. Topline records from the Part II look for the remedy of T2D are anticipated within the third quarter of 2026.
“ASC30 has doable to be essentially one of the top-in-class oral miniature molecule GLP-1 for obesity, evidenced by its efficacy and tolerability demonstrated by the U.S. Part II look in participants with obesity or overweight,” said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, “Expanding ASC30’s scientific pattern into the colossal diabetes remedy market is a logical subsequent step that offers us with one other chance to concentrate on ASC30’s doable easiest-in-class profile as a as soon as-day-to-day oral remedy possibility for patients. We wait for sharing topline records from the Part II look in diabetes participants within the third quarter of 2026.”
Dr. Wu added, “In accordance to the sure scientific results announced in December 2025 from our 13-week U.S. Part II look of ASC30 in participants with obesity or overweight, the Firm expects to manufacture the clearance from the U.S. Food and Drug Administration and originate Part III trials within the U.S. for obesity indication by the dwell of the third quarter 2026.”
ASC30 used to be found and developed in-condominium at Ascletis as a first and most effective investigational miniature molecule GLP-1R entirely biased agonist that will most likely be dosed as soon as day-to-day orally and as soon as month-to-month to as soon as quarterly subcutaneously for the remedy of obesity, diabetes and diversified metabolic ailments.
Referring to the U.S. Part II Gaze with ASC30 for the Medication of Diabetes
The Part II look is a 13-week, randomized, double-blind, placebo-managed and multi-heart look to abet in mind the efficacy, safety, and tolerability of ASC30 tablets in participants with form 2 diabetes mellitus. The first endpoint of the Part II look is the imply commerce from baseline in HbA1c up to 13 weeks within the remedy community compared with the placebo community. Secondary endpoints encompass the imply commerce from baseline in fasting blood glucose up to 13 weeks within the remedy community compared with the placebo community, the imply commerce from baseline in physique weight up to 13 weeks within the remedy community compared with placebo community, and safety and tolerability. The Part II look enrolled 100 participants with form 2 diabetes mellitus at just a few sites across the U.S. People were randomly assigned in a ratio of roughly 2:3:3:2 to 40 mg, 60 mg and 80 mg ASC30 tablets and matching placebo tablets, respectively. ASC30 used to be titrated weekly from 1 mg to target doses of 40 mg, 60 mg and 80 mg.
About Ascletis Pharma Inc.
Ascletis Pharma Inc. is a actually built-in biotechnology company centered on the diagram and commercialization of doable easiest-in-class and first-in-class therapeutics to take care of metabolic ailments. Utilizing its proprietary Man made Intelligence-assisted Constructing-Essentially essentially based Drug Discovery (AISBDD) and Extremely-Lengthy-Acting Platform (ULAP) technologies as properly as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed just a few drug candidates in-condominium, at the side of both miniature molecules and peptides, comparable to its lead program, ASC30, a miniature molecule GLP-1R agonist designed to be administered as soon as day-to-day orally and as soon as month-to-month to as soon as quarterly subcutaneously as a remedy therapy and a maintenance therapy for chronic weight management; ASC36, an amylin receptor peptide agonist, ASC35, a as soon as-month-to-month subcutaneously administered GLP-1R/GIPR twin peptide agonist and ASC37, a GLP-1R/GIPR/GCGR triple peptide agonist, ASC39, a potent and amylin-selective oral miniature molecule amylin receptor agonist, and ASC30_39 FDC, a fixed-dose aggregate (FDC) of ASC30 and ASC39, for chronic weight management. Ascletis is listed on the Hong Kong Stock Alternate (1672.HK).
For extra files, please search the recommendation of with www.ascletis.com.
Contact:
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Ascletis Pharma Inc. PR and IR Groups
+86-181-0650-9129 (China)
Look usual teach to download multimedia: https://www.prnewswire.com/news-releases/ascletis-completes-enrollment-in-us-portion-ii-look-of-asc30-an-oral-miniature-molecule-glp-1r-agonist-for-the-remedy-of-diabetes-302753633.html
SOURCE Ascletis Pharma Inc.
